CMF for breast Ca does make a difference
Adjuvant treatment with cyclophosphamide, methotrexate, and fluorouracil (CMF) in women with operable breast cancer at risk of relapse halves that threat and reduces the risk of death with minimal long-term sequelae.
Adjuvant treatment with cyclophosphamide, methotrexate, and fluorouracil (CMF) in women with operable breast cancer at risk of relapse halves that threat and reduces the risk of death with minimal long-term sequelae.
Italian researchers conducted a cohort study in which they reviewed nearly 30 years' worth of data from three randomized controlled studies and one observational study conducted previously at the Istituto Nazionale Tumori in Milan.
They found that the adjuvant treatment regimen reduced the relative risk of relapse significantly (hazard ratio 0.71, 95% CI; 0.56-0.91, P=0.005), as well as the risk of death (0.79, 0.63-0.98, P=0.04). They found six cycles to be sufficient, with no additional benefit conferred by 12.
Pruritic rash in vulvovaginal area of 2-year-old girl
May 12th 2023Three months ago, a healthy 2-year-old girl presented with a mildly pruritic rash with erythematous plaques, some silvery white, in the vulvovaginal area. She had no vaginal discharge or other symptoms. The rash is now more widespread, and new lesions have recently appeared on her lower back and thighs. What's the diagnosis?
Read More
Association between skin pre-aging, psychological stress less widely-known among young women
April 20th 2023Research indicates that despite reports of high psychological stress among women in their 20s and 30s in China and Japan, awareness of stress’s effects on aging remain higher among health professionals.
Read More
Researchers investigate psoriasis and adverse pregnancy outcomes
July 14th 2022A study published in JAAD International examined the association between psoriasis and adverse pregnancy outcomes (APOs) and found that providers should be on the lookout for ectopic pregnancies (EP) in this population.
Read More
